Interleukin-2 (IL-2) Receptor Agonist Pipeline Insight, 2018 Report - ResearchAndMarkets.com

November 30, 2018

DUBLIN--(BUSINESS WIRE)--Nov 30, 2018--The “Interleukin-2 (IL-2) Receptor Agonist -Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

‘Interleukin-2 (IL-2) Receptor Agonist - Pipeline Insight, 2018’ reportoffers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Interleukin-2 (IL-2) Receptor Agonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Interleukin-2 (IL-2) Receptor Agonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Interleukin-2 (IL-2) Receptor Agonist

The report assesses the active Interleukin-2 (IL-2) Receptor Agonist pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the report:

Provides a snapshot of the therapeutics pipeline activity for Interleukin-2 (IL-2) Receptor Agonist Features the Interleukin-2 (IL-2) Receptor Agonist pipeline across the complete product development cycle including all clinical and non-clinical stages Offers detailed therapeutic product profiles of Interleukin-2 (IL-2) Receptor Agonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration Coverage of dormant and discontinued pipeline projects across Interleukin-2 (IL-2) Receptor Agonist

Reasons to Purchase:

Establish a comprehensive understanding of the current pipeline scenario across Interleukin-2 (IL-2) Receptor Agonist to formulate effective R&D strategies Assess challenges and opportunities that influence Interleukin-2 (IL-2) Receptor Agonist research & development (R&D) Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage Identify and understand the sought after therapy areas and indications for Interleukin-2 (IL-2) Receptor Agonist Identify the product attributes and use it for target finding, drug repurposing, and precision medicine Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Interleukin-2 (IL-2) Receptor Agonist to enhance and expand business potential and scope Plan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress Our extensive domain knowledge on therapy areas supports the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

Key Topics Covered:

1. Report Introduction

2. Interleukin-2 (IL-2) Receptor Agonist - Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Interleukin-2 (IL-2) Receptor Agonist

4. Comparative Analysis

5. Interleukin-2 (IL-2) Receptor Agonist Pipeline Products in Clinical Stages

Product Description Research and Development Product Development Activities

Other product profiles in the detailed report..

6. Interleukin-2 (IL-2) Receptor Agonist Pipeline Products in Non-clinical Stages

Product Description Research and Development Product Development Activities

7. Therapeutic Assessment: Active Products

Pipeline Assessment by Route of Administration Pipeline Assessment by Stage and Route of Administration Pipeline Assessment by Molecule Type Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

Product Description Research and Development Product Development Activities Reason for dormancy/discontinuation

Companies Mentioned

Bayer Philogen Carlina Technologies EMD Serono Merck Serono Pfizer Celgene Corporation Nanogen Biopharmaceutical Co XEME Biopharma Micromet Inc Medicenna Therapeutics Nektar Therapeutics

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/7j4329/interleukin2?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181130005365/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs,Immunosuppressive Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 11/30/2018 12:06 PM/DISC: 11/30/2018 12:06 PM


Update hourly